

AMENDMENTS TO THE SPECIFICATION

Please delete the reaction scheme beginning on line 5 of page 41 of the specification.

Please replace the following reaction schemes with the replacement reaction schemes presented in Appendix B. Annotated versions of the reaction schemes indicating the changes made are presented in Appendix C.

EXAMPLE**LOCATION**

Example 1

Page 19, line 9.

Example 2

Page 32, line 4.

Example 3

Page 36, line 7

Example 5

Page 43, line 4

Please replace the following tables with the replacement tables presented in Appendix D. Annotated versions of the tables indicating the changes made are presented in Appendix E.

TABLE**LOCATION**

Table 1

Beginning on page 21, line 2, and ending on page 31, line 11.

Table 2


Beginning on page 33, line 23, and ending on page 35, line 25.

Table 6

Beginning on page 47, line 17, and ending on page 49, line 15.


Please replace the Abstract on page 65 of the Application with the following paragraph:

A compound having the formula:




wherein: R_1 is $-X-R_1'$; in which R_1' is lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl, or heterocyclic, and X is $-NH-$; R_2 is isopropyl; and R_3 is $-NR_4R_5$; in which R_4 is hydrogen and R_5 is lower alkyl substituted with amino or R_4 and R_5 are both lower alkyl substituted with one, two or three groups chosen from hydroxy and amino, or an acid addition salt or cationic salt thereof. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.


Replacement Scheme
Example 1, Page 19, Line 9



Replacement Scheme
Example 2, Page 32, Line 4



Replacement Scheme
Example 3, Page 36, Line 7



Marked Up Replacement Scheme
Example 5, Page 43, Line 4

